

5-Hydroxytryptamine Receptor 7 - Drugs In Development, 2021

<https://marketpublishers.com/r/51D9F66B2C3AEN.html>

Date: June 2021

Pages: 85

Price: US\$ 3,500.00 (Single User License)

ID: 51D9F66B2C3AEN

Abstracts

5-Hydroxytryptamine Receptor 7 - Drugs In Development, 2021

SUMMARY

According to the recently published report '5-Hydroxytryptamine Receptor 7 - Drugs In Development, 2021'; 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) pipeline Target constitutes close to 15 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes.

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - 5-HT7 receptor is a member of the GPCR superfamily and it is activated by the serotonin (5-HT). The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It plays an important role in autistic disorder and other neuropsychiatric disorders.

The report '5-Hydroxytryptamine Receptor 7 - Drugs In Development, 2021' outlays comprehensive information on the 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are

1, 4, 1, 5 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Report covers products from therapy areas Central Nervous System, Cardiovascular, Gastrointestinal and Respiratory which include indications Bipolar Disorder (Manic Depression), Schizophrenia, Anxiety Disorders, Autism, Depression, Neuropathic Pain (Neuralgia), Psychiatric Disorders, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder (ADHD), Cognitive Disorders, Crohn's Disease (Regional Enteritis), Dementia Associated With Alzheimer's Disease, Generalized Anxiety Disorder (GAD), Idiopathic Pulmonary Fibrosis, Inflammatory Pain, Major Depressive Disorder, Parkinson's Disease, Psychosis, Pulmonary Arterial Hypertension, Schizoaffective Disorder, Sleep Disorders and Ulcerative Colitis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)

The report reviews 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics and enlists all their major and minor projects

The report assesses 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or

Serotonin Receptor 7 or HTR7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) -
Overview

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) -
Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) -
Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) -
Companies Involved in Therapeutics Development

Adamed Sp zoo

Avineuro Pharmaceuticals Inc

Celon Pharma SA

Core One Labs Inc

Daya Drug Discoveries Inc

H. Lundbeck AS

Johnson & Johnson

LB Pharmaceuticals Inc

Praeventix LLC

Reviva Pharmaceuticals Inc

Sumitomo Dainippon Pharma Co Ltd

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) -
Drug Profiles

ADN-1184 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADN-3662 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVN-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brilaroxazine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DDD-028 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dimethyl tryptamine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-18038683 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LB-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LB-102 LA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LB-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lurasidone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize 5-HT7 for Neuropathic Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize 5 HT7 Receptors for Crohn's Disease and Ulcerative Colitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target 5-HT7R for Sleep Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vortioxetine hydrobromide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Dormant Products

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Discontinued Products

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Product Development Milestones

Featured News & Press Releases

May 03, 2021: H. Lundbeck: New study finds that vortioxetine helps patients with MDD and comorbid Generalized Anxiety Disorder

May 03, 2021: Sunovion presents data from marketed and late-stage development psychiatric compounds at the American Psychiatric Association (APA) Annual Meeting 2021

Apr 26, 2021: Reviva announces full details of positive phase 2 clinical trial results for acute Schizophrenia

Apr 22, 2021: Vortioxetine significantly improves overall functioning in a global real-world study in Major Depressive Disorder

Feb 02, 2021: LB Pharmaceuticals announces the initiation of patient dosing in open label phase 1b imaging study of LB-102

Sep 17, 2020: Lundbeck presents positive data from the COMPLETE study with vortioxetine

Sep 14, 2020: LB Pharmaceuticals announces results of LB-102 phase 1 first-in-human clinical study

Sep 02, 2020: LB Pharmaceuticals announces the Hiring of Dr. Anna Eramo as Chief

Medical Officer

Jul 23, 2020: CHMP recommended extensions of indication for Latuda

Jun 06, 2020: Celon Pharma signs an agreement with the National Centre for Research and Development (NCRD) for subsidising the Company's subsequent projects

Mar 25, 2020: Sumitomo Dainippon Pharma announces approval of atypical antipsychotic agent, LATUDA tablets in Japan

Jan 23, 2020: LB Pharmaceuticals starts dosing of schizophrenia drug

Oct 09, 2019: ChemRar Group of Companies announces the successful completion of the second phase of clinical trials of an innovative drug for the treatment of generalized anxiety disorder

Sep 20, 2019: Takeda and Lundbeck's Trintellix approved in Japan for depression

Sep 03, 2019: Sumitomo Dainippon Pharma Announces the Launch of Atypical Antipsychotic LATUDA in China

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Adamed Sp zoo, 2021
Pipeline by Avineuro Pharmaceuticals Inc, 2021
Pipeline by Celon Pharma SA, 2021
Pipeline by Core One Labs Inc, 2021
Pipeline by Daya Drug Discoveries Inc, 2021
Pipeline by H. Lundbeck AS, 2021
Pipeline by Johnson & Johnson, 2021
Pipeline by LB Pharmaceuticals Inc, 2021
Pipeline by Praeventix LLC, 2021
Pipeline by Reviva Pharmaceuticals Inc, 2021
Pipeline by Sumitomo Dainippon Pharma Co Ltd, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

I would like to order

Product name: 5-Hydroxytryptamine Receptor 7 - Drugs In Development, 2021

Product link: <https://marketpublishers.com/r/51D9F66B2C3AEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/51D9F66B2C3AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970